Answer
Cobimetinib directly targets MEK1 and MEK2 through reversible, selective, allosteric inhibition, thereby inhibiting ERK1 and ERK2 phosphorylation and blocking MAPK signalling.
Sources for this answer
- Cotellic 20 mg film-coated tabletsRoche Products Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 14Document updated
Sources checked